Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Electrum Advances AMT Geophysical Survey Identifying Additional Drill Targets (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Omeros Corporation OMER

Healthcare Biotechnology
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:OMER)

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Business Wire December 26, 2025

FDA Approves Omeros' YARTEMLEA® - First and Only Therapy Indicated for TA-TMA

Business Wire December 24, 2025

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Business Wire December 1, 2025

Omeros Corporation Reports Third Quarter 2025 Financial Results

Business Wire November 13, 2025

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Business Wire November 11, 2025

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Business Wire October 16, 2025

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Business Wire September 2, 2025

Omeros Corporation Reports Second Quarter 2025 Financial Results

Business Wire August 14, 2025

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Business Wire August 11, 2025
View More News ››

Opinion & Analysis (NDAQ:OMER)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:OMER)

Buy buddy buy.

Otherwise FOMO
coolfooldumbguy - October 15, 2025

Omeros Corporation (NASDAQ:OMER): A Promising Biotech Poised

http://beyondspx.com/2024/08/01/omeros-corporation-nasdaqomer-a-promising-biotech-poised-for-significant-growth/
MikeTester - August 2, 2024
View more Bullboard ››

Pelangio Exploration Inc.

Pelangio Exploration Inc.

Pelangio Exploration Inc., a mineral exploration company, engages in the acquisition, exploration, and development of mineral ...
View More »

Podcasts